false 0001625101 0001625101 2026-06-11 2026-06-11
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): June 11, 2026
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
 
On June 11, 2026, Pulse Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting:
 
 
1.
to elect seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal;
 
 
2.
to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;
 
The voting results for each of these proposals are detailed below:
 
 
1.
Election of Directors
 
Nominee
  
For
  
Against
  
Abstained
  
Broker Non-votes
Robert W. Duggan
   33,443,582  
1,583,174
  
388
  
10,974,550
Paul A. LaViolette
   34,264,295  
759,401
  
3,448
  
10,974,550
Maria Sainz   35,007,101   18,349   1,694   10,974,550
Manmeet S. Soni
   33,560,875  
1,464,574
  
1,695
  
10,974,550
Darrin R. Uecker
   34,246,413  
779,036
  
1,695
  
10,974,550
Richard A. van den Broek
   34,278,978  
746,471
  
1,695
  
10,974,550
Mahkam Zanganeh, D.D.S.
   34,241,938  
783,511
  
1,695
  
10,974,550
 
Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.
 
 
2.
Ratification of Appointment of Independent Registered Public Accounting Firm
 
For
  
Against
  
Abstained
  
Broker Non-votes
45,976,355
  
8,265
  
17,074
  
N/A
 
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: June 11, 2026
By:
/s/ Jon Skinner
  
   
Jon Skinner
  
   
Chief Financial Officer
(Principal Financial Officer)
  
 
 
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: plse20260607c_8k_htm.xml